Historical Valuation
Inhibrx Biosciences Inc (INBX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.80. The fair price of Inhibrx Biosciences Inc (INBX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：72.86
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Inhibrx Biosciences Inc (INBX) has a current Price-to-Book (P/B) ratio of 29.54. Compared to its 3-year average P/B ratio of 6.02 , the current P/B ratio is approximately 390.47% higher. Relative to its 5-year average P/B ratio of 6.02, the current P/B ratio is about 390.47% higher. Inhibrx Biosciences Inc (INBX) has a Forward Free Cash Flow (FCF) yield of approximately -13.14%. Compared to its 3-year average FCF yield of -65.21%, the current FCF yield is approximately -79.85% lower. Relative to its 5-year average FCF yield of -65.21% , the current FCF yield is about -79.85% lower.
P/B
Median3y
6.02
Median5y
6.02
FCF Yield
Median3y
-65.21
Median5y
-65.21
Competitors Valuation Multiple
AI Analysis for INBX
The average P/S ratio for INBX competitors is 8.49, providing a benchmark for relative valuation. Inhibrx Biosciences Inc Corp (INBX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for INBX
1Y
3Y
5Y
Market capitalization of INBX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of INBX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is INBX currently overvalued or undervalued?
Inhibrx Biosciences Inc (INBX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.80. The fair price of Inhibrx Biosciences Inc (INBX) is between to according to relative valuation methord.
What is Inhibrx Biosciences Inc (INBX) fair value?
INBX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Inhibrx Biosciences Inc (INBX) is between to according to relative valuation methord.
How does INBX's valuation metrics compare to the industry average?
The average P/S ratio for INBX's competitors is 8.49, providing a benchmark for relative valuation. Inhibrx Biosciences Inc Corp (INBX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Inhibrx Biosciences Inc (INBX) as of Jan 10 2026?
As of Jan 10 2026, Inhibrx Biosciences Inc (INBX) has a P/B ratio of 29.54. This indicates that the market values INBX at 29.54 times its book value.
What is the current FCF Yield for Inhibrx Biosciences Inc (INBX) as of Jan 10 2026?
As of Jan 10 2026, Inhibrx Biosciences Inc (INBX) has a FCF Yield of -13.14%. This means that for every dollar of Inhibrx Biosciences Inc’s market capitalization, the company generates -13.14 cents in free cash flow.
What is the current Forward P/E ratio for Inhibrx Biosciences Inc (INBX) as of Jan 10 2026?
As of Jan 10 2026, Inhibrx Biosciences Inc (INBX) has a Forward P/E ratio of -13.38. This means the market is willing to pay $-13.38 for every dollar of Inhibrx Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Inhibrx Biosciences Inc (INBX) as of Jan 10 2026?
As of Jan 10 2026, Inhibrx Biosciences Inc (INBX) has a Forward P/S ratio of 0.00. This means the market is valuing INBX at $0.00 for every dollar of expected revenue over the next 12 months.